Identifying a new blood cancer to improve the outlook for leukaemia patients
Looking at a new subtype of leukaemia, called CML-like Ph+ALL, to see how best to diagnose and treat it.
What factors affect the survival of children and young people with high-risk acute lymphoblastic leukaemia?
Finding out what makes ALL more high-risk, such as age of diagnosis or type of initial treatment.
Understanding why some childhood blood cancers are incurable
Using models to find out how high risk leukaemia cells grow and become resistant to treatment.
How do leukaemia stem cells talk to the immune system in juvenile myelomonocytic leukaemia?
Find out how JMML cells are able to switch off the immune system, causing relapse.
Creating a new immunotherapy approach to fight aggressive medulloblastoma
Finding a way to use immunotherapy against a high-risk type of childhood brain tumour.
Confirming bloodstream markers of children’s kidney cancer
Identifying markers that can be used for a non-invasive test to diagnose and monitor Wilms tumour.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
New treatments for relapsed rhabdomyosarcoma
Developing better models of rhabdomyosarcoma to test available treatments.
Investigating how regulatory regions of the genome communicate with cancer causing genes
Finding which regulatory regions of the genome are causing leukaemia by acting on the wrong gene